# OnCo record obinutuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/obinutuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "obinutuzumab" ;
  schema:name "Obinutuzumab"@en ;
  schema:description "Obinutuzumab is a glycoengineered CD20 antibody that recruits immune cells and kills B cells more directly than rituximab. Paired with venetoclax for a fixed 12 months in chronic lymphocytic leukaemia, it keeps over half of patients treatment-free six years later, and it is also used in follicular lymphoma; first-dose infusion reactions are common and managed by splitting the dose."@en ;
  schema:url <https://onco.cc/drugs/obinutuzumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Obinutuzumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q389496> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Obinutuzumab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-CD20, glycoengineered type II)" ;
  schema:alternateName "Gazyva" ;
  onco:approval "US 2013: Previously untreated CLL with chlorambucil (CLL11)", "US 2019: Previously untreated CLL with venetoclax, fixed duration (CLL14); with acalabrutinib (ELEVATE-TN)" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll-treatment-naive/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd20/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/complement-in-cancer/> ;
  onco:terms <https://onco.cc/terms/adcc/> ;
  onco:trials <https://onco.cc/trials/cll14/>, <https://onco.cc/trials/cll13-gaia/>, <https://onco.cc/trials/elevate-tn/>, <https://onco.cc/trials/nct05100862/>, <https://onco.cc/trials/nct04077723/>, <https://onco.cc/trials/nct06090539/>, <https://onco.cc/trials/nct05533775/>, <https://onco.cc/trials/nct04787042/>, <https://onco.cc/trials/nct03075696/>, <https://onco.cc/trials/nct03930953/>, <https://onco.cc/trials/nct05673057/>, <https://onco.cc/trials/nct06943872/>, <https://onco.cc/trials/nct06084936/>, <https://onco.cc/trials/nct06428019/>, <https://onco.cc/trials/nct06634589/>, <https://onco.cc/trials/nct03533283/>, <https://onco.cc/trials/nct06806033/>, <https://onco.cc/trials/nct05057494/>, <https://onco.cc/trials/nct04895436/>, <https://onco.cc/trials/nct07520006/>, <https://onco.cc/trials/nct06970743/> .